SIGA Technologies, Inc. (SIGA) - 10-K Summary
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: SIGA is a commercial-stage pharmaceutical company focused on the development and sale of TPOXX® (tecovirimat), an antiviral drug for the treatment of smallpox. The company sells oral and intravenous (IV) formulations primarily to the U.S. Government (Strategic National Stockpile and Department of Defense) and international governments. The company relies on third-party Contract Manufacturing Organizations (CMOs) for production.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $94.6 million | $138.7 million |
| Net Income | $23.3 million | $59.2 million |
| Operating Income | $23.7 million | $70.0 million |
| Net Cash from Operating Activities | $43.5 million | $48.8 million |
| Cash and Cash Equivalents (Ending) | $155.0 million | $155.4 million |
| Inventory | $49.1 million | $49.6 million |
| Effective Tax Rate | 23.4% | 22.2% |
| Diluted EPS | $0.32 | $0.82 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 32% to $94.6 million from $138.7 million. This was driven primarily by a significant drop in international sales ($5.8 million in 2025 vs. $23.0 million in 2024) and lower U.S. Government oral TPOXX® sales ($53.3 million vs. $73.9 million).
- Profitability Compression: Net income fell 61% to $23.3 million. While operating expenses decreased slightly, the revenue decline was the primary driver. Research and development expenses increased 62% to $20.0 million due to self-funded activities and headcount increases.
- Contract Value Increases: The 19C BARDA Contract total value increased by $27.5 million in 2025 (to approx. $630 million) due to amendments for manufacturing support and pediatric formulation development.
- Dividend Payment: The company paid a special dividend of $0.60 per share in May 2025, totaling approximately $43.1 million.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Risk (Mpox Indication): The European Medicines Agency (EMA) initiated a referral procedure for Tecovirimat-SIGA following clinical trial results (PALM007, STOMP, UNITY) that did not meet primary endpoints for mpox treatment. SIGA expects the EMA to recommend withdrawal of the mpox indication while maintaining approvals for smallpox, cowpox, and vaccinia complications. A similar reassessment is ongoing in the UK.
- Manufacturing Transition: SIGA is transitioning IV TPOXX® manufacturing from Patheon (which is closing the line in 2026) to a new third-party site. This process is complex and requires FDA approval for the new facility.
- Government Contract Dependence: Future revenue is heavily dependent on the U.S. Government exercising options under the 19C BARDA Contract and securing new procurement contracts. The company notes that government contracts are subject to funding uncertainties and potential termination.
- Outlook: Management believes current cash resources are sufficient for at least the next 12 months. The company is targeting a Supplemental NDA submission for smallpox post-exposure prophylaxis (PEP) within the next 12 months.
Key Facts for Investor Verification
- Contract Option Exercise: Verify the status of the $545.2 million in exercised options under the 19C BARDA Contract and the timeline for future deliveries to ensure revenue recognition assumptions hold.
- International Sales Recovery: Assess the company's ability to rebuild international sales following the 75% drop in 2025, particularly given the potential loss of the mpox indication in Europe.
- Manufacturing Transition Risks: Monitor the progress of the IV TPOXX® manufacturing site transfer to ensure no delays in fulfilling government obligations.
- Regulatory Decisions: Track the final EMA and MHRA recommendations regarding the mpox indication, as this could impact future international demand.
- Cash Burn vs. Revenue: Evaluate the sustainability of the business model given the significant revenue decline while R&D expenses increased, despite a strong cash position of $155 million.